Haemonetics (NYSE:HAE) posted third-quarter results on Thursday that cleared analyst estimates, proving that its aggressive move toward high-margin medical technologies is successfully offsetting the loss of legacy revenue streams.
The Boston-based medical technology leader reported adjusted earnings of $1.31 per share, beating the Zacks Consensus estimate of $1.27.
While reported revenue of $339 million was down 2.7% year-over-year, the figure masked a strong underlying performance: excluding the planned transition of its CSL Plasma supply agreement and the divestiture of its Whole Blood business, organic revenue grew 7.5%.
The strategy of "quality over quantity" was evident in the company's adjusted gross margin, which expanded by 250 basis points to 60.2%.
The quarter’s outperformance was driven by the Plasma and Blood Management segments.
The Plasma business grew 3.5% to $138.9 million, buoyed by market share gains and the continued global rollout of the NexSys PCS® collection system.
Meanwhile, despite a relatively flat top-line performance in the Hospital unit, the company successfully integrated its recent acquisitions of Opsens and Attune Medical, and announced the full acquisition of Vivasure Medical in January 2026 to bolster its vascular closure portfolio.